Clinical Features and Prognostic Analysis of Diffuse Large B-Cell Lymphoma in the Elderly.
10.19746/j.cnki.issn.1009-2137.2025.05.014
- Author:
Li-Yuan CHU
1
;
Ding-Dan ZHANG
1
;
Ya-Yue ZHANG
1
;
Qiu-Yue FAN
1
;
Shao-Dan TIAN
1
Author Information
1. Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
diffuse large B-cell lymphoma in the elderly;
prognostic factors;
survival analysis;
clinical features
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse/diagnosis*;
Prognosis;
Aged;
Male;
Female;
Survival Rate;
Proportional Hazards Models;
Aged, 80 and over;
Kaplan-Meier Estimate;
Neoplasm Staging
- From:
Journal of Experimental Hematology
2025;33(5):1327-1334
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognostic factors of elderly patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:Clinical data of elderly DLBCL patients diagnosed pathologically between 2010 and 2015 were extracted from the SEER database. Cox proportional hazards model was used for multivariate analysis, and Kaplan-Meier survival curves were plotted to explore the prognostic factors affecting overall survival (OS).
RESULTS:A total of 11 523 elderly DLBCL patients were included, of whom 58.6% had stage Ⅲ/Ⅳ disease, and 28.8% exhibited extranodal involvement. Besides lymph nodes (68.5%), common primary extranodal sites included the gastrointestinal tract (9.8%) and lip, mouth, and pharynx (4.1%). The median survival time for the entire cohort was 47 months, with a 3-year survival rate of 52.0%, and a 5-year survival rate of 47.8%. Multivariate Cox regression analysis revealed that age, sex, race, Ann Arbor stage, primary site, B symptoms, treatment modality, treatment sequence, and whether DLBCL was the first malignant primary indicator were independent prognostic factors affecting OS in elderly DLBCL patients (all P <0.05).
CONCLUSION:Age≥70 years, male, black race, advanced Ann Arbor stage, primary sites in the lungs, liver, or kidney, presence of B symptoms, and preoperative systemic therapy were independent risk factors for poor prognosis in elderly DLBCL patients.
